Category CAR-T

PIER MARIA FORNASARI
2022-10-14

Results of a phase 1 UCART19 trial, a first-in-class allogeneic anti-CD19 CART-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM) published in The Lancet Haematology

The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-09-27

Calibr, a Division of Scripps Research, reports promising results from first-in-human clinical trial of switchable CAR-T (CLBR001 + SWI019), a next-generation universal CAR-T platform designed to enhance the versatility and safety of cell therapies

In preliminary results from a Phase I study of CLBR001 + SWI019 for patients with B cell malignancies: 7 of 9 patients responded and 6 of 9 had a complete response (78% ORR, 67% CR) CLBR001 cells engrafted at higher levels than approved CAR-T cell products without causing an increase in the incidence of CRS

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-09

Higher doses of CAR T cell therapy associate with improved outcomes in young patients with B-ALL : a report from the pediatric real-world CAR consortium

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.   Since its approval as the first

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-06

St. Jude Researchers improved CAR T-cell therapy for T-cell acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital developed a simple method to select for more effective cancer-destroying CAR T cells for patients with relapsed T-ALL. Scientists at St. Jude Children’s Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against relapsed T-cell

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-06-12

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

CNS relapse is still a common cause of treatment failure in R/R B-ALL, although chemotherapy, cranial irradiation, and allo-HSCT are all modalities that can be incorporated into the management of CNSL. In the present study, published on Blood by a team of Xuzhou Medical University, was reported the efficacy, toxicity, and clinical feasibility of CD19-specific

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-04-11

FDA approves axicabtagene ciloleucel CAR-T cells for second-line treatment of large B-cell lymphoma

On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was

Read More

No Comments InCAR-T